Sign Up to like & get
recommendations!
0
Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e16656
Abstract: 511Background: Neoadjuvant immunotherapy with anti-programmed cell death protein-1 (PD-1) or anti-programmed cell death ligand-1 (PD-L1) and tyrosine kinase inhibitor (TKI) therapy is currently bei...
read more here.
Keywords:
immunotherapy;
targeted therapies;
effect neoadjuvant;
neoadjuvant immunotherapy ... See more keywords